Consensus ratings from healthcare equity research analysts regarding Novartis AG generally lean toward a hold or moderate buy recommendation, reflecting a balanced institutional outlook. Supporters highlight the company's strong pharmaceutical portfolio, innovative drug pipeline, and stable dividend yield, while cautious observers monitor patent expirations and macroeconomic pressures across the global healthcare sector before committing capital.